证券代码：600056 证券简称：中国医药 公告编号：临2026-012号 中国医药健康产业股份有限公司 关于公司涉及诉讼事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要提示： 1．案件所处的诉讼阶段：法院已作出二审（终审）判决； 2．上市公司所处的当事人地位：上诉人（一审原告）； 近日，中国医药健康产业股份有限公司（以下简称"公司"）收到北京市高级人民法院送达的《民事判决 书》[(2025)京民终659号]，具体情况如下： 一、本次诉讼案件的基本情况 2024年10月，因业绩补偿引起的合同纠纷，公司作为原告向北京市第二中级人民法院提交《民事起诉 状》，对西藏天晟泰丰药业股份有限公司（以下简称"西藏天晟"）及徐攀峰提起诉讼，请求判令西藏天 晟向公司支付业绩补偿款100,631,772.46元和逾期支付利息，公司有权在业绩补偿款和逾期支付利息债 权范围内对西藏天晟持有的河南通用30%股权（对应出资额300万元）拍卖、变卖后所得价款优先受 偿，徐攀峰对西藏天晟在业绩补偿款和逾期支付利息债权范围内向公司承担连带清 ...

证券代码：600056 证券简称：中国医药 公告编号：临 2026-012 号 中国医药健康产业股份有限公司 关于公司涉及诉讼事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要提示： 1．案件所处的诉讼阶段：法院已作出二审（终审）判决； 2．上市公司所处的当事人地位：上诉人（一审原告）； 3．涉案金额：13,940.41万元； 4．对上市公司损益产生的影响：上述判决为终审判决,公司前期已进行了相 关会计处理,公司将继续依据有关会计准则的要求和终审判决结果进行相应的会 计处理,最终影响以年度审计机构审计确认后的结果为准。 近日，中国医药健康产业股份有限公司（以下简称"公司"）收到北京市 高级人民法院送达的《民事判决书》[(2025)京民终 659 号]，具体情况如下： 一、本次诉讼案件的基本情况 2024 年 10 月，因业绩补偿引起的合同纠纷，公司作为原告向北京市第二中 级人民法院提交《民事起诉状》，对西藏天晟泰丰药业股份有限公司（以下简称 "西藏天晟"）及徐攀峰提起诉讼，请求判令西藏天晟向公司支付业绩补偿款 ...

Core Viewpoint - China Medical announced that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for two drug registration certificates for Dabigatran Etexilate Capsules, a direct thrombin inhibitor used for various thromboembolic conditions [1] Group 1: Product Information - Dabigatran Etexilate is primarily used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevent DVT and PE recurrence [1] - The drug was developed by Boehringer Ingelheim and was launched in Germany and the UK in March 2008, received FDA approval in October 2010, and was launched in China in February 2013 [1] Group 2: Market Context - As of the announcement date, besides Tianfang Pharmaceutical, 13 other companies, including Chengdu Baitai Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., and Chengdu Yuandong Biopharmaceutical Co., Ltd., have obtained production licenses for this drug in China [1] - According to a third-party database, the sales revenue of this drug in China's three major terminal markets is projected to be approximately 571 million yuan in 2024, with an estimated 375 million yuan in the first three quarters of 2025 [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Dabigatran Etexilate Capsules, which will enhance its product portfolio and provide valuable experience for future generic drug development [1][6]. Group 1: Drug Registration Information - The drug name is Dabigatran Etexilate Capsules, with acceptance numbers CYHS2401330 and CYHS2401331, and registration certificate numbers 2026S00242 and 2026S00243 [1]. - The drug is available in capsule form with specifications of 150mg and 110mg [1]. - The approval was granted based on compliance with the relevant requirements of the Drug Administration Law of the People's Republic of China [1]. Group 2: Drug Characteristics and Market Situation - Dabigatran Etexilate is a direct thrombin inhibitor used to reduce the risk of stroke and systemic embolism in non-valvular atrial fibrillation, treat deep vein thrombosis and pulmonary embolism, and prevent recurrence of these conditions [2]. - The drug was developed by Boehringer Ingelheim and was first launched in Germany and the UK in March 2008, received FDA approval in October 2010, and was launched in China in February 2013 [2]. - As of the announcement date, 13 other companies, including Chengdu Better Pharmaceutical Co., Ltd. and Jiangsu Hengrui Medicine Co., Ltd., have also obtained production licenses for this drug [5]. - The sales revenue of the drug in China was approximately 571 million yuan in 2024, with about 375 million yuan in the first three quarters of 2025 [5]. Group 3: Financial Investment - The total investment in the raw material and formulation project for the drug is approximately 28 million yuan (unaudited) [4].

Core Viewpoint - China National Pharmaceutical Group Co., Ltd. announced that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the registration of Dabigatran Etexilate Capsules, which will enhance the company's product line and development experience in generic drugs [1] Group 1: Product Approval and Specifications - The approved drug includes two specifications: 110mg and 150mg [1] - The drug is primarily used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis and pulmonary embolism [1] Group 2: Financial and Market Impact - The drug registration application was accepted in May 2024, with a total investment of approximately 28 million RMB [1] - According to data from Minet, the estimated sales revenue for the drug in China's three major terminal markets in 2024 is approximately 571 million RMB [1] Group 3: Competitive Landscape and Future Outlook - Currently, there are 14 manufacturers, including Tianfang Pharmaceutical, that have obtained approval for this drug in China [1] - The company indicated that future sales may be influenced by national policies and market conditions, which could lead to performance that does not meet expectations [1]

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical (600253) has received two drug registration certificates for Dabigatran Etexilate capsules from the National Medical Products Administration [1] Group 1: Product Approval - Tianfang Pharmaceutical received approval for two specifications of Dabigatran Etexilate capsules: 150mg and 110mg [1] - Dabigatran Etexilate is a direct thrombin inhibitor used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation [1] Group 2: Indications and Uses - The drug is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) [1] - It is also used to lower the risk of recurrence of DVT and PE, as well as for the prevention of DVT and PE following hip replacement surgery [1]

Group 1 - Far East Holdings announced that its subsidiary won a contract order worth 3.075 billion yuan, including contracts for green building cables and smart manufacturing cables [1] - Yifan Pharmaceutical received a drug registration certificate for Vitamin K1 injection, which is used to treat vitamin K deficiency-related bleeding [2] - Guangdong Electric Power A's Maoming Bohua Power Plant's Unit 4 has successfully commenced commercial operation, with a total investment of 7.484 billion yuan and an expected annual power generation of 8.6 billion kWh [4] Group 2 - Longfly Fiber reported that the global fiber optic cable industry market environment is normal, with product price fluctuations needing comprehensive assessment [25] - Shanghai Yizhong's net profit for 2025 increased by 819.42%, with total revenue of 317 million yuan, a growth of 82.72% [22] - Guizhou Power's subsidiary received a government subsidy of 200 million yuan [8] Group 3 - Zhongxing Communications plans to invest 117 million yuan in the Jianxing Zhanlu Fund, which focuses on new information technology and advanced manufacturing [10] - Suwen Electric Power's subsidiary established a joint investment fund with a total commitment of 68.5 million yuan, with Suwen contributing 5 million yuan [26] - ST Kaiyuan announced that its stock may face delisting risk due to expected negative net assets for 2025 [27]

证券代码：600056 证券简称：中国医药 公告编号：临 2026-011 号 中国医药健康产业股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司天方药业有限公司（以下简称"天方药业"）收到国家药品监督管理局（以下 简称"国家药监局"）核准签发的两份达比加群酯胶囊（以下简称"该药品"） 《药品注册证书》，现将有关情况公告如下： 二、药品其他相关情况 （一）达比加群酯属于直接凝血酶抑制剂，主要用于减少非瓣膜性心房颤动 的中风和全身性栓塞风险、治疗深静脉血栓形成和肺栓塞、降低深静脉血栓形成 和肺栓塞复发的风险、髋关节置换手术后深静脉血栓形成和肺栓塞的预防。达比 加群酯胶囊由德国勃林格殷格翰公司开发，于 2008 年 3 月在德国和英国上市， 2010 年 l0 月获美国 FDA 批准上市，2013 年 2 月在国内上市。 （二）国家药监局于 2024 年 5 月受理该药品的注册申请。 一、注册证书基本信息 药品名称： ...

中国医药健康产业股份有限公司 2026 年第一次临时股东会会议文件 证券代码：600056 证券简称：中国医药 2026 年第一次临时股东会 会议资料 2026 年 2 月 9 日 北京市丰台区西营街 1 号院 1 区 1 号楼 28 层 中国医药健康产业股份有限公司 2026 年第一次临时股东会会议文件 目录 | 议案一 | 关于确定第十届董事会非独立董事薪酬的议案 | ... 1 | | --- | --- | --- | | | 关于确定第十届董事会独立董事报酬的议案 | 2 | | | 关于选举非独立董事的议案 | 3 | | | 关于选举独立董事的议案 | 5 | | 议案二 议案三 议案四 | | | 中国医药健康产业股份有限公司 2026 年第一次临时股东会会议文件 议案一 关于确定第十届董事会非独立董事薪酬的议案 各位股东： 根据董事会薪酬与考核委员会提议，经第九届董事会第 35 次会议审议通过如下董事薪酬相关事项： 一、按照公司相关薪酬制度、标准和管理办法，在公司 任职的第十届董事会非独立董事的薪酬实行固定薪酬与绩 效薪酬相结合的方式，其中：固定薪酬根据不同岗位标准按 月发放，绩效薪酬根据绩 ...

Group 1 - China National Pharmaceutical Group announced that its wholly-owned subsidiary, Tianfang Pharmaceutical, received two drug registration certificates for Dabigatran Etexilate Capsules from the National Medical Products Administration [1] - The product name is "Dabigatran Etexilate Capsules" [1] Group 2 - Automotive sales giant Baolide, previously known for selling luxury cars like Rolls-Royce and Porsche, is now undergoing bankruptcy liquidation [1] - The headquarters in Hangzhou has been vacated, and the subsidiary in Yiwu has been sealed [1]